(PharmaNewsWire.Com, September 08, 2017 ) Ovarian cancer occurs when cell growth in the ovarian tissue becomes uncontrollable. Ovarian cancer is one of the most common causes of death in women across the world. There is a need for development of new medication and therapies for the proper treatment of this ailment, and newer techniques for the timely diagnosis of ovarian cancer Market. Hence, the market for ovarian cancer therapeutics has a great potential.
The treatment of ovarian cancer is done depending on the stage the disease is in. The treatment includes surgery, radiation, chemotherapy, and biological therapy. It is also known that ovarian cancer is the most chemo-sensitive cancer. Chemotherapy treatment is more effective when combined with radiation therapy.
Cases of ovarian cancer have grown rapidly, as a result, so has its Europe therapeutics market. One of the factors is increase in aging of the women population. Introduction of new drugs and effective therapies, increase in people’s disposable income, and better government funding and support are some of the key factors behind the growth of global ovarian cancer market. Additionally, increasing awareness about healthcare is also propelling the growth of the ovarian cancer market. Recent launches of generic drugs, and expiration of patents of blockbuster drugs, such as Taxol, Gemzar, Paraplatin and Hycamtin are some of the key factors restraining the growth for ovarian cancer market.
The Europe ovarian cancer market is segmented based on the stage of cancer as Stage I, Stage II, Stage III and Stage IV. Stages of cancer are further sub-segmented into Stage IA, Stage IB, Stage IC, Stage IIA, Stage IIB, Stage IIC, Stage IIIA, Stage IIIB and Stage IIIC. By cancer type, it is segmented into Primary Peritoneal Carcinoma, Ovarian Stromal Tumors, Ovarian Germ Cell Tumors and Epithelial Ovarian Tumors. By Diagnosis, it is further segmented into Physical Examination, Blood Tests, Ultrasound, PET, CT Scan, MRI, Human Chorionic Gonadotropin Test and Biopsy, By type of treatment, it is segmented into Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery, Immunotherapy and Targeted Therapy. Futhermore, on the basis of geography, the Europe market is analysed under various regions namely UK, Spain, Italy, Germany and France. North American region, in particular, US is the largest market for Ovarian cancer. Europe is the second largest market as the cases of ovarian cancer are very high too.
Some of the major players in this market are Aetera Zenteris Inc., Eli Lilly and Company, Roche, Amgen, Janssen Pharmaceuticals, Inc., Bristol Myers Squibb Company, Novogen, Inc., GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Genentech Inc. About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions. Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: abhishek@marketdataforecast.com Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/ View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
